+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
540359 PARMAX

Parmax Pharma Share Price

 
Stock touched 52W high

 

Parmax Pharma live price: ₹50.98. It opened at ₹46 vs previous close ₹44; intraday high/low: ₹53/₹46. The 50 & 200 DMA stand at ₹33.57/₹33.84.

Parmax Pharma Performance

  • Today's Low
  • ₹46
  • Today's High
  • ₹53
  • 52 Week Low
  • ₹23
  • 52 Week High
  • ₹53
  • Open Price₹46
  • Previous Close₹44
  • Volume62,597
  • 50 DMA₹33.57
  • 100 DMA₹32.93
  • 200 DMA₹33.84

Parmax Pharma Chart

Investment Returns

  • Over 1 Month + 69.82%
  • Over 3 Month + 54.63%
  • Over 6 Month + 50.87%
  • Over 1 Year + 26.16%

Smart Investing Starts Here Start SIP with Parmax Pharma for Steady Growth!

Invest Now

Parmax Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -4.6
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 19
  • P/B Ratio
  • -3
  • Average True Range
  • 3.1
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 1.68
  • RSI
  • 74.91
  • MFI
  • 96.3

Parmax Pharma Financials

Parmax Pharma Technicals

EMA & SMA

Current Price
₹50.98
+ 6.49 (14.59%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹36.12
  • 50 Day
  • ₹33.57
  • 100 Day
  • ₹32.93
  • 200 Day
  • ₹33.84

Resistance and Support

42.16 Pivot Speed
  • R3 55.33
  • R2 50.16
  • R1 47.33
  • S1 39.33
  • S2 34.16
  • S3 31.33

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Parmax Pharma has an operating revenue of Rs. 13.62 Cr. on a trailing 12-month basis. An annual revenue growth of 154% is outstanding, Pre-tax margin of -8% needs improvement, NULL It has recently broken out of a base in its weekly chart and is trading around 5% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 85 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 70 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has some relative strength and buyer demand but we want to see further fundamental performance to qualify as a growth stock. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Parmax Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-06-02 Audited Results (Revised)
2026-02-14 Quarterly Results
2025-11-14 Quarterly Results
2025-08-14 Quarterly Results
2025-05-30 Audited Results

Parmax Pharma Shareholding Pattern

30.8%
63.11%
6.09%

Parmax Pharma FAQs

Parmax Pharma share price is ₹50 As on 04 June, 2026 | 11:35

The Market Cap of Parmax Pharma is ₹19.1 Cr As on 04 June, 2026 | 11:35

The P/E ratio of Parmax Pharma is -4.6 As on 04 June, 2026 | 11:35

The PB ratio of Parmax Pharma is -3 As on 04 June, 2026 | 11:35

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23